← Back to Search

Other

A Study of LY3857210 in Healthy Participants

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through study completion, up to approximately 6 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug, LY3857210, in healthy people to see how it behaves in the brain using special brain scans. The study also checks if the drug is safe and tolerable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through study completion, up to approximately 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through study completion, up to approximately 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in brain receptor occupancy (RO) of LY3857210 measured by [18F]-LY3818850 PET scan

Side effects data

From 2023 Phase 2 trial • 131 Patients • NCT05620576
6%
Urinary tract infection
5%
Headache
5%
Pain in extremity
3%
Vulvovaginal candidiasis
3%
Neuropathy peripheral
2%
Dizziness
1%
Back pain
1%
Cellulitis
1%
Subcutaneous abscess
1%
Fall
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
45 mg LY3857210

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: LY3857210Experimental Treatment1 Intervention
Single doses of LY3857210 administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3857210
2022
Completed Phase 2
~430

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,374 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,831 Total Patients Enrolled
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top